Clinical characteristics and outcomes in participants with screen-detected clinical stage I lung cancer in the Yorkshire lung screening trial: A comparison of surgery versus stereotactic ablative radiotherapy
Cancer-specific survival was similar between the two groups, but overall survival following SABR for screen-detected stage I lung cancer is worse than surgery due to higher rates of non-cancer death within 5 years of treatment. Lung cancer sojourn time has been estimated at around 5 years, so it is likely that rates of overdiagnosis are higher in patients treated with SABR compared to surgery. Further research may be needed to optimise inclusion and exclusion criteria for lung cancer screening.
Authors
- K. Franks (ORCID: https://orcid.org/0000-0001-9468-7947)
- Rhian Gabe (ORCID: https://orcid.org/0000-0002-0273-3094)
- Daniel Vulkan (ORCID: https://orcid.org/0000-0003-4738-9378)
- Hannah Bailey (ORCID: https://orcid.org/0009-0009-8953-9777)
- Matthew Callister (ORCID: https://orcid.org/0000-0001-8157-0803)
- H. Tam (ORCID: https://orcid.org/0000-0002-8542-1749)
- Philip Crosbie (ORCID: https://orcid.org/0000-0001-8941-4813)
- Alessandro Brunelli (ORCID: https://orcid.org/0000-0002-6505-1656)
- Martyn Kennedy
Institutions
- Queen Mary University of London (GB)
- Leeds Teaching Hospitals NHS Trust (GB)
- University of Manchester (GB)
Publication Details
- Journal
- Lung Cancer
- Published
- 2025-11-03
- DOI
- https://doi.org/10.1016/j.lungcan.2025.108816
- Primary Topic
- Lung Cancer Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00